Neutralizing antibody against granulocyte/macrophage colony-stimulating factor inhibits inflammatory response in experimental otitis media

Laryngoscope

Volumn 123, Issue 6, 2013, Pages 1514-1518

  Kariya, Shin ^a   Okano, Mitsuhiro ^a   Higaki, Takaya ^a   Makihara, Seiichiro ^a   Haruna, Takenori ^a   Eguchi, Motoharu ^a   Nishizaki, Kazunori ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

chemokine; cytokine; endotoxin; Granulocyte macrophage colony stimulating factor; lipopolysaccharide; middle ear; otitis

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHEMOATTRACTANT; CHEMOKINE; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUTRALIZING ANTIBODY; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; INFLAMMATION; KERATINOCYTE; MIDDLE EAR EFFUSION; MOUSE; NEUTROPHIL; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UPREGULATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED C57BL; OTITIS MEDIA;

EID: 84878154916     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23795     Document Type: Article

References (22)

1. Luong A, Roland PS,. The link between allergic rhinitis and chronic otitis media with effusion in atopic patients. Otolaryngol Clin North Am 2008; 41: 311-323.
2. Juhn SK, Jung MK, Hoffman MD, et al. The role of inflammatory mediators in the pathogenesis of otitis media and sequelae. Clin Exp Otorhinolaryngol 2008; 1: 117-138.
3. Leichtle A, Lai Y, Wollenberg B, Wasserman SI, Ryan AF,. Innate signaling in otitis media: pathogenesis and recovery. Curr Allergy Asthma Rep 2011; 11: 78-84.
4. Smirnova MG, Birchall JP, Pearson JP,. The immunoregulatory and allergy-associated cytokines in the aetiology of the otitis media with effusion. Mediators Inflamm 2004; 13: 75-88.
5. Hamilton JA,. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544.
6. Yellon RF, Leonard G, Marucha PT, et al. Characterization of cytokines present in middle ear effusions. Laryngoscope 1991; 101: 165-169.
7. Himi T, Suzuki T, Kodama H, Takezawa H, Kataura A,. Immunologic characteristics of cytokines in otitis media with effusion. Ann Otol Rhinol Laryngol Suppl 1992; 157: 21-25.
8. Smirnova MG, Birchall JP, Pearson JP,. Evidence of T-helper cell 2 cytokine regulation of chronic otitis media with effusion. Acta Otolaryngol 2005; 125: 1043-1050.
9. Kariya S, Okano M, Aoji K, et al. Role of macrophage migration inhibitory factor in otitis media with effusion in adults. Clin Diagn Lab Immunol 2003; 10: 417-422.
10. Kariya S, Schachern PA, Cureoglu S, et al. Up-regulation of macrophage migration inhibitory factor induced by endotoxin in experimental otitis media with effusion in mice. Acta Otolaryngol 2008; 128: 750-755.
11. Eguchi M, Kariya S, Okano M, et al. Lipopolysaccharide induces proinflammatory cytokines and chemokines in experimental otitis media through the prostaglandin D2 receptor (DP)-dependent pathway. Clin Exp Immunol 2011; 163: 260-269.
12. DeMaria TF, Murwin DM,. Tumor necrosis factor during experimental lipopolysaccharide-induced otitis media. Laryngoscope 1997; 107: 369-372.
13. Maeda K, Hirano T, Ichimiya I, Kurono Y, Suzuki M, Mogi G,. Cytokine expression in experimental chronic otitis media with effusion in mice. Laryngoscope 2004; 114: 1967-1972.
14. Puljic R, Benediktus E, Plater-Zyberk C, et al. Lipopolysaccharide- induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol 2007; 557: 230-235.
15. Vlahos R, Bozinovski S, Chan SP, et al. Neutralizing granulocyte/ macrophage colony-stimulating factor inhibits cigarette smoke-induced lung inflammation. Am J Respir Crit Care Med 2010; 182: 34-40.
16. Vlahos R, Bozinovski S, Hamilton JA, Anderson GP,. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol Ther 2006; 112: 106-115.
17. Khameneh HJ, Isa SA, Min L, Nih FW, Ruedl C,. GM-CSF signalling boosts dramatically IL-1 production. PLoS One 2011; 6: e23025.
18. Brissette WH, Baker DA, Stam EJ, Umland JP, Griffiths RJ,. GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF. Cytokine 1995; 7: 291-295.
19. Munker R, Gasson J, Ogawa M, Koeffler HP,. Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature 1986; 323: 79-82.
20. Traves SL, Donnelly LE,. Th17 cells in airway diseases. Curr Mol Med 2008; 8: 416-426.
21. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP,. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 554-559.
22. Codarri L, Gyulveszi G, Tosevski V, et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12: 560-567.